Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

PolyTherics, Spirogen enter research collaboration to produce novel ADCs for treatment of cancer

PolyTherics Limited, a provider of solutions to enable the development of better biopharmaceuticals, and Spirogen Limited, a leading oncology-focused company developing DNA sequence-targeted agents, announce that they have formed a research collaboration to develop antibody drug conjugates that combine PolyTherics' proprietary site-specific conjugation chemistry with Spirogen's highly potent novel cytotoxic drugs to produce novel ADCs for the treatment of cancer.

2 Apr 2012

New treatment approach halts spread of cancer cells into normal brain tissue

Treating invasive brain tumors with a combination of chemotherapy and radiation has improved clinical outcomes, but few patients survive longer than two years after diagnosis. The effectiveness of the treatment is limited by the tumor's aggressive invasion of healthy brain tissue, which restricts chemotherapy access to the cancer cells and complicates surgical removal of the tumor.

29 Mar 2012

Researchers design new treatment approach for invasive brain tumors

Researchers from Emory and the Georgia Institute of Technology have designed a new treatment approach that appears to halt the spread of cancer cells into normal brain tissue in animal models.

29 Mar 2012

FDA clears BD MAX assay for detecting GBS DNA in Lim Broth cultures

BD announced today the U.S. Food and Drug Administration clearance of the BD MAX Group B Streptococcus (GBS) Assay and Clinical Laboratory Improvement Amendments (CLIA) moderate complexity test categorization on the second-generation BD MAX System.

From BD (Becton, Dickinson and Company) 29 Mar 2012

Gold nanoparticles used to introduce chemical residues into the immune system

Developing a drug or vaccine requires a delicate balancing act with the immune system. On one hand, medications need to escape detection by the immune system in order to perform their function. But vaccinations - de-activated versions of a disease or virus - need to do the reverse. They prompt the immune system to create protective antibodies.

27 Mar 2012

UC professor to show new anticancer agent at ACS Spring 2012 meeting

Advances in chemotherapy have dramatically improved the outlook for many cancer patients, but the side effects of this treatment are daunting. A new generation of chemotherapy drugs with fewer side effects is the goal of Edward J. Merino, assistant professor of chemistry at the University of Cincinnati.

27 Mar 2012

Pharmaplan, Moberg Derma to distribute Nalox/Emtrix in South Africa

Moberg Derma AB has entered into a distribution agreement with Pharmaplan (Pty) Ltd. for Nalox//Emtrix - for discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis.

27 Mar 2012

ACS symposium focuses on biomimetics

Combining the secrets that enable water striders to walk on water and give wood its lightness and great strength has yielded an amazing new material so buoyant that, in everyday terms, a boat made from 1 pound of the substance could carry five kitchen refrigerators, about 1,000 pounds.

27 Mar 2012

Bolus intracoronary abciximab reduces infarct size in high-risk patients with STEMI

Administration of a bolus dose of the anticoagulant drug abciximab into the coronary artery involved in causing a certain type of heart attack among patients who were undergoing a percutaneous coronary intervention and also receiving another anticoagulant resulted in reduction in the size of damage to the heart muscle at 30 days, while a procedure that involved use of a catheter to remove the blood clot blocking that coronary artery did not produce these results, according to a study appearing in JAMA.

27 Mar 2012

TOLMAR, Impax Labs partner for alternative dosage form products

Impax Laboratories, Inc. and TOLMAR, Inc. today announced that they will collaborate on a multiproduct agreement for the development, supply and distribution of alternative dosage form products.

26 Mar 2012

Global Fund spotlights contributions of public-private partnerships in event on Capitol Hill

"At a public event held Tuesday on Capitol Hill, the Global Fund to Fight AIDS, Tuberculosis and Malaria and Friends of the Global Fight Against AIDS, Tuberculosis and Malaria spotlighted the contributions of public-private partnerships to the Global Fund's lifesaving work," a joint press release reports.

22 Mar 2012

PEGPH20 enzyme re-expands insides of blood vessels to allow more drugs to reach tumours

Cancer Research UK scientists have shown that an enzyme can re-expand the insides of blood vessels allowing more drugs and large antibody molecules to reach pancreatic tumours, according to research published in GUT today.

21 Mar 2012

$Enrollment commences in MORE Registry for DBS in patients with refractory epilepsy$

Enrollment commences in MORE Registry for DBS in patients with refractory epilepsy

Medtronic, Inc. today announced that a patient from Kempenhaeghe-Heeze (The Netherlands) is the first patient to be enrolled into the MORE (MedtrOnic Registry for Epilepsy) Registry which is designed to look at the long-term efficacy, quality of life impact and safety of deep brain stimulation (DBS) in patients with refractory epilepsy.

From Medtronic 17 Mar 2012

Echo total revenues increase to $447,000 for fiscal year 2011

Echo Therapeutics, Inc., a company developing its needle-free Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude SkinPrep System for transdermal drug delivery, today announced financial results for the year ended December 31, 2011.

17 Mar 2012

$Health Canada grants license to Medtronic DBS Therapy for refractory epilepsy$

Health Canada grants license to Medtronic DBS Therapy for refractory epilepsy

Medtronic, Inc. today announced that it has received from Health Canada a license for Medtronic Deep Brain Stimulation (DBS) Therapy for refractory epilepsy patients.

From Medtronic 16 Mar 2012

EffRx receives FDA approval for BINOSTO to treat osteoporosis

EffRx Pharmaceuticals SA today announced that the U.S. Food and Drug Administration (FDA) has approved BINOSTO (alendronate sodium) Effervescent Tablets, previously known as EX101, for the treatment of osteoporosis in postmenopausal women, and as a treatment to increase bone mass in men with osteoporosis. EffRx anticipates that BINOSTO will be commercially available in the United States in the third quarter of 2012.

15 Mar 2012

Biomedical research advances through new Australian Institute

The Institute of Biomedical Engineering and Technology (BMET) will be officially opened this evening at the University of Sydney, and will significantly advance this highly multidisciplinary research for life sciences and medicine.

14 Mar 2012

BDSI announces postponement of ONSOLIS U.S. relaunch

BioDelivery Sciences International, Inc. today announced that the U.S. relaunch of ONSOLIS (fentanyl buccal soluble film) is being postponed until the product formulation can be modified to address two appearance issues raised by the U.S. Food and Drug Administration (FDA) following a recent inspection of the Aveva manufacturing facility where ONSOLIS is produced.

12 Mar 2012

Antares Pharma fourth quarter revenues increase 65% to $5.4 million

Antares Pharma, Inc. today reported financial and operating results for the fourth quarter and full year ended December 31, 2011 and outlined key objectives and milestones for 2012.

12 Mar 2012

InflammaGen to initiate Phase 2 study of new drug/delivery platform for shock

A 200-patient Phase 2 clinical pilot study will be initiated this month to test the efficacy and safety of a new use, and method of administering, an enzyme inhibitor for critically ill patients developed by University of California, San Diego Bioengineering Professor Geert Schmid-Sch-nbein. Conditions expected to qualify for the study include new-onset sepsis and septic shock, post-operative complications, and new-onset gastrointestinal bleeding.

12 Mar 2012